Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Berenberg lowers target price on Whitbread, cites 'anaemic' UK hotel demand

(Sharecast News) - Analysts at Berenberg lowered their target price on Premier Inn owner Whitbread from 3,900.0p to 3,500.0p on Thursday as it noted that UK hotel demand has "remained anaemic" year-to-date. Berenberg now forecasts negative revenue per available room growth in FY26 as a result of weak demand but noted that despite this, it was encouraged by the company's outperformance versus the wider market, the ongoing inflexion in Germany and its previously announced property valuation, which it thinks could be a "positive catalyst".

The German bank, which reiterated its 'buy' rating on the stock, noted that in its most recent set of results, Whitbread reiterated that its five-year plan remained on track to deliver incremental profit of at least £300.0m by FY30, while also generating more than £2.0bn in shareholder returns.

Berenberg also highlighted that since the plan was announced in October 2024, the UK market has continued to soften and cost inflation has risen as a result of changes to UK National Insurance costs. However, Whitbread has also expressed confidence in its cost-saving plans, which could help to offset this.

"That being said, both we and consensus forecast lower incremental profit. By FY30, we forecast an incremental £220.0m of PBT on what was delivered in FY25. However, this number is very sensitive to RevPAR and accommodation sales, with a 1% growth shift worth £16m-£17m of PBT in FY26. Therefore, if RevPAR growth outperforms our estimate, we would gain more confidence that its target for £300m of incremental profit by FY30 is achievable," said Berenberg.

Reporting by Iain Gilbert at Sharecast.com

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.